117 related articles for article (PubMed ID: 16998813)
1. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
Steiner H; Cavarretta IT; Moser PL; Berger AP; Bektic J; Dietrich H; Zaki MH; Nakada M; Hobisch A; Nemeth JA; Culig Z
Prostate; 2006 Dec; 66(16):1744-52. PubMed ID: 16998813
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
3. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
[TBL] [Abstract][Full Text] [Related]
4. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
Pitulis N; Papageorgiou E; Tenta R; Lembessis P; Koutsilieris M
Anticancer Res; 2009 Jun; 29(6):2331-7. PubMed ID: 19528499
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 regulation of prostate cancer cell growth.
Culig Z; Steiner H; Bartsch G; Hobisch A
J Cell Biochem; 2005 Jun; 95(3):497-505. PubMed ID: 15838876
[TBL] [Abstract][Full Text] [Related]
6. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
Potiron VA; Sharma G; Nasarre P; Clarhaut JA; Augustin HG; Gemmill RM; Roche J; Drabkin HA
Cancer Res; 2007 Sep; 67(18):8708-15. PubMed ID: 17875711
[TBL] [Abstract][Full Text] [Related]
9. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
10. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.
Steiner H; Godoy-Tundidor S; Rogatsch H; Berger AP; Fuchs D; Comuzzi B; Bartsch G; Hobisch A; Culig Z
Am J Pathol; 2003 Feb; 162(2):655-63. PubMed ID: 12547723
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 is regulated by IL-6 and mediates the survival activity of the cytokine in a model of late stage prostate carcinoma.
Cavarretta IT; Neuwirt H; Zaki MH; Steiner H; Hobisch A; Nemeth JA; Culig Z
Adv Exp Med Biol; 2008; 617():547-55. PubMed ID: 18497081
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization and modulation of p44/42 mitogen-activated protein kinase by 2-Methoxyestradiol in prostate cancer models.
Casarez EV; Dunlap-Brown ME; Conaway MR; Amorino GP
Cancer Res; 2007 Sep; 67(17):8316-24. PubMed ID: 17804747
[TBL] [Abstract][Full Text] [Related]
13. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6.
Steiner H; Berger AP; Godoy-Tundidor S; Bjartell A; Lilja H; Bartsch G; Hobisch A; Culig Z
Eur J Cancer; 2004 May; 40(7):1066-72. PubMed ID: 15093584
[TBL] [Abstract][Full Text] [Related]
14. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
Venkateswaran V; Haddad AQ; Fleshner NE; Fan R; Sugar LM; Nam R; Klotz LH; Pollak M
J Natl Cancer Inst; 2007 Dec; 99(23):1793-800. PubMed ID: 18042933
[TBL] [Abstract][Full Text] [Related]
15. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
Zhang W; Chen Y; Wei H; Zheng C; Sun R; Zhang J; Tian Z
Clin Cancer Res; 2008 Oct; 14(20):6432-9. PubMed ID: 18927282
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice.
Smith PC; Keller ET
Prostate; 2001 Jun; 48(1):47-53. PubMed ID: 11391686
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
18. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
Weng JR; Tsai CH; Kulp SK; Wang D; Lin CH; Yang HC; Ma Y; Sargeant A; Chiu CF; Tsai MH; Chen CS
Cancer Res; 2007 Aug; 67(16):7815-24. PubMed ID: 17699787
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
20. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
